Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Ständer, Sonja; Yosipovitch, Gil; Legat, Franz J.; Lacour, J; Paul, C.; Narbutt, Joanna; Bieber, Thomas; Miséry, Laurent; Wollenberg, Andreas; Reich, Adam; Ahmad, Faiz; Piketty, Christophe

doi:10.1056/nejmoa1908316

Cited by 220 publications

(194 citation statements)

References 18 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…Table 1 shows the subjects' baseline demographic characteristics. In line with other trials in CP/CPN subjects, 28 women are more represented (83% of the evaluated group). Chronic pruritus Figure 3 shows OCT images of one subject.…”

Section: Resultssupporting

confidence: 88%

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments

Ardigò

Franceschini

Campione

et al. 2020

CCID

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 88%

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments

Ardigò

Franceschini

Campione

et al. 2020

CCID

View full text Add to dashboard Cite

“…181 The difficult-to-treat subgroup of patients with prurigoform AD may profit especially well from nemolizumab. 182 A proof-of-concept study reported a rapid and sustained effect of a single administration of etokimab, an anti-IL-33 monoclonal antibody, in patients with AD. 183 The ETFAD recommends checking on a regular basis all upcoming information in this field, as the licensing of new drugs for the treatment of AD is likely.…”

Section: Biologics In Clinical Trialsmentioning

confidence: 99%

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

Wollenberg

Christen-Zäch

Taı̈eb

et al. 2020

Acad Dermatol Venereol

301

360

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and burden are best measured with a composite score, assessing both objective and subjective symptoms, such as SCORing Atopic Dermatitis (SCORAD). AD management must take into account clinical and pathogenic variabilities, the patient's age and also target flare prevention. Basic therapy includes hydrating and barrierstabilizing topical treatment universally applied, as well as avoiding specific and unspecific provocation factors. Visible skin lesions are treated with anti-inflammatory topical agents such as corticosteroids and calcineurin inhibitors (tacrolimus and pimecrolimus), which are preferred in sensitive locations. Topical tacrolimus and some mid-potency corticosteroids are proven agents for proactive therapy, which is defined as the long-term intermittent anti-inflammatory therapy of frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is a rapidly changing † See Appendix section.

show abstract

“…Currently, a clinical trial is enrolling to evaluate the use of dupilumab in patients with PN who are not adequately controlled by topical therapies [ 13 ]. Additionally, a recent phase 2 trial involving nemolizumab, which inhibits IL-31 receptor A, suggested efficacy over placebo but was associated with gastrointestinal and musculoskeletal adverse events [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series

Wieser

Mercurio

Somers

2020

Cureus

View full text Add to dashboard Cite

Prurigo nodularis is a pruritic skin condition that can present therapeutic challenges. We present a series of three patients diagnosed with prurigo nodularis who had failed several commonly trialed therapies, but experienced relief from symptoms and improvement in skin lesions following initiation of dupilumab therapy. All patients in this series lacked a diagnosis of atopic dermatitis and had lesions on the lower extremities, although other locations such as the trunk were also involved. Continued study of dupilumab in patients with prurigo nodularis is advocated.

show abstract

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Cited by 220 publications

References 18 publications

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series

Contact Info

Product

Resources

About